FDA’s December 2025 OPOE list features 784 prescription drugs, 73 OTC drugs
This
week, PharmaCompass brings you key highlights of the US Food and Drug Administration’s D
FDA’s first generic approvals slump 21% in 2024; Novartis’ top seller Entresto, cancer blockbuster Tasigna lead 2024 patent cliff
A watershed moment in the journey of a drug is when it transitions from being a patented, high‐

Market Place
Sourcing Support